Payment overview · 2025
General Payments
$3,512.47
177 reported records · 23 companies
Healthcare provider profile · identity verified
Frank David Kondos, MD
Allopathic & Osteopathic Physicians|Family Medicine · TULSA, OK · NPI 1952415366
Verified facts
What the public records show
CMS Open Payments records show Frank David Kondos, MD received $3,512.47 in general payments during 2025 across 177 reported records.
AstraZeneca Pharmaceuticals LP accounted for 13.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $476.90 | 13.6% | 24 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $367.71 | 10.5% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $317.55 | 9.0% | 24 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $286.84 | 8.2% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $280.93 | 8.0% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $270.63 | 7.7% | 13 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $253.05 | 7.2% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $241.91 | 6.9% | 11 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $199.53 | 5.7% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $186.86 | 5.3% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $96.65 | 2.8% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $91.66 | 2.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.63 | 2.5% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $64.07 | 1.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $59.12 | 1.7% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.91 | 1.5% | 3 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $39.68 | 1.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $38.98 | 1.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.00 | 1.0% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.89 | 0.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.14 | 0.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.77 | 0.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.06 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,512.47 | 177 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $494.96 | 25 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $328.14 | 16 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $280.93 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $258.01 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $224.25 | 13 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $213.38 | 14 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $199.53 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $168.81 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $162.83 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $148.64 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $143.65 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $129.35 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $112.98 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $96.65 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $91.66 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $71.69 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $71.11 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.13 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $64.99 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $64.07 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $61.66 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $55.84 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $51.91 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $48.04 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $48.04 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $48.04 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.86 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.76 | 3 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $39.68 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $38.98 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $34.00 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 150 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 191 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 251 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 154 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
107 | 24 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
191 | 32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
191 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
251 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
154 | 23 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
150 | 29 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 870 | 120 |
| Atorvastatin Calcium | Atorvastatin Calcium | 779 | 199 |
| Alprazolam | Alprazolam | 669 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 621 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 532 | 136 |
| Gabapentin | Gabapentin | 473 | 90 |
| Lisinopril | Lisinopril | 418 | 113 |
| Zolpidem Tartrate | Zolpidem Tartrate | 385 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 381 | 90 |
| Losartan Potassium | Losartan Potassium | 316 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 259 | 73 |
| Omeprazole | Omeprazole | 257 | 73 |
| Mounjaro | Tirzepatide | 251 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 244 | 53 |
| Diazepam | Diazepam | 244 | 53 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 244 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 58 |
| Metformin Hcl | Metformin Hcl | 224 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 223 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 53 |
| Oxycodone Hcl | Oxycodone Hcl | 211 | 25 |
| Bupropion Xl | Bupropion Hcl | 199 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 192 | 47 |
| Jardiance | Empagliflozin | 191 | 32 |
| Potassium Chloride | Potassium Chloride | 191 | 55 |
| Trazodone Hcl | Trazodone Hcl | 186 | 45 |
| Meloxicam | Meloxicam | 185 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 173 | 39 |
| Furosemide | Furosemide | 173 | 48 |
| Azithromycin | Azithromycin | 167 | 131 |
| Tizanidine Hcl | Tizanidine Hcl | 167 | 32 |
| Allopurinol | Allopurinol | 164 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 161 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 161 | 45 |
| Clonazepam | Clonazepam | 160 | 26 |
| Pregabalin | Pregabalin | 158 | 22 |
| Ozempic | Semaglutide | 154 | 23 |
| Eliquis | Apixaban | 150 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 41 |
| Lorazepam | Lorazepam | 147 | 22 |
| Irbesartan | Irbesartan | 146 | 35 |
| Metformin Hcl Er | Metformin Hcl | 143 | 41 |
| Tramadol Hcl | Tramadol Hcl | 142 | 25 |
| Promethazine Hcl | Promethazine Hcl | 131 | 22 |
| Sertraline Hcl | Sertraline Hcl | 124 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 119 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 38 |
| Carvedilol | Carvedilol | 117 | 26 |
| Ondansetron Odt | Ondansetron | 111 | 30 |
| Synthroid | Levothyroxine Sodium | 107 | 24 |
| Celecoxib | Celecoxib | 104 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 104 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 102 | 75 |
| Montelukast Sodium | Montelukast Sodium | 97 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 95 | 23 |
| Ezetimibe | Ezetimibe | 91 | 20 |
| Buspirone Hcl | Buspirone Hcl | 90 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 14 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 84 | suppressed |
| Simvastatin | Simvastatin | 84 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 22 |
| Baclofen | Baclofen | 80 | 19 |
| Atenolol | Atenolol | 77 | 20 |
| Methylprednisolone | Methylprednisolone | 77 | 54 |
| Estradiol | Estradiol | 76 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 75 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 74 | 12 |
| Fentanyl | Fentanyl | 73 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 20 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 69 | 16 |
| Spironolactone | Spironolactone | 64 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 62 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 13 |
| Warfarin Sodium | Warfarin Sodium | 61 | suppressed |
| Verapamil Er | Verapamil Hcl | 56 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 41 |
| Alendronate Sodium | Alendronate Sodium | 54 | 17 |
| Temazepam | Temazepam | 54 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 43 |
| Nebivolol Hcl | Nebivolol Hcl | 52 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 52 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | suppressed |
| Aripiprazole | Aripiprazole | 49 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 49 | 13 |
| Prednisone | Prednisone | 49 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | suppressed |
| Eszopiclone | Eszopiclone | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 12 |
| Famotidine | Famotidine | 46 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 45 | suppressed |
| Acyclovir | Acyclovir | 41 | 19 |
| Finasteride | Finasteride | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 13 |
| Glipizide | Glipizide | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | 33 |
| Fluconazole | Fluconazole | 38 | 19 |
| Raloxifene Hcl | Raloxifene Hcl | 38 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 37 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Glimepiride | Glimepiride | 35 | 12 |
| Methocarbamol | Methocarbamol | 34 | 15 |
| Methylphenidate Hcl | Methylphenidate Hcl | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 18 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 11 |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 11 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Lubiprostone | Lubiprostone | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Methadone Hcl | Methadone Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 13 |
| Nystatin | Nystatin | 19 | 11 |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Dulera | Mometasone/Formoterol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Belbuca | Buprenorphine Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Forteo | Teriparatide | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Ambien | Zolpidem Tartrate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Celebrex | Celecoxib | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,512.47 · 177 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, Azstarys, BOTOX, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Symbravo, TONMYA, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error